Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts

Author:

Passamonti Francesco1,Maffioli Margherita1,Cervantes Francisco2,Vannucchi Alessandro Maria3,Morra Enrica4,Barbui Tiziano5,Caramazza Domenica1,Pieri Lisa3,Rumi Elisa6,Gisslinger Heinz7,Knoops Laurent8,Kiladjian Jean Jaques9,Mora Barbara1,Hollaender Norbert10,Pascutto Cristiana6,Harrison Claire11,Cazzola Mario6

Affiliation:

1. Division of Hematology, Department of Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy;

2. Hematology Department, Hospital Clínic, Institut d'investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;

3. Section of Hematology, Department of Critical Care, University of Florence, Florence, Italy;

4. Division of Hematology, Ospedale Niguarda Cà Granda, Milano, Italy;

5. Hematology Department and Research Foundation, Ospedali Riuniti, Bergamo, Italy;

6. Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy;

7. Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria;

8. Service d’Hematologie Cliniques universitaires Saint-Luc and Institut de Duve, Universite Catholique de Louvain, Brussels, Belgium;

9. Hôpital Saint-Louis and Université Paris Diderot, Paris, France;

10. Novartis Pharma AG, Basel, Switzerland; and

11. Guy’s and St. Thomas’ National Health Service Foundation Trust, Guy’s Hospital, London, United Kingdom

Abstract

Key PointsPatients with primary myelofibrosis and intermediate-2 or high IPSS risk have a median life expectancy of 4 years or less. PMF patients with higher IPSS risks who receive ruxolitinib treatment have longer survival than those who receive conventional therapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 85 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3